Zomedica Pharmaceuticals Corp Cash Flow-to-Debt Ratio
Zomedica Pharmaceuticals Corp cash flow-to-debt ratio. Zomedica Pharmaceuticals Corp (ZOM) has a Cash Flow-to-Debt Ratio of -0.63x as of March 2025, meaning its operating cash flow of $-6.65 Million could theoretically repay -1% of its total liabilities ($10.55 Million) in one year. See ZOM financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Zomedica Pharmaceuticals Corp (2013–2024)
Cash flow-to-debt ratio of Zomedica Pharmaceuticals Corp from 2013 to 2024. Historical debt coverage capacity for Zomedica Pharmaceuticals Corp across 12 annual periods. Check Zomedica Pharmaceuticals Corp cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Zomedica Pharmaceuticals Corp Cash Flow-to-Debt Ratio by Year (2013–2024)
Zomedica Pharmaceuticals Corp cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for Zomedica Pharmaceuticals Corp. For the full cash flow conversion analysis, see Zomedica Pharmaceuticals Corp operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.02x | $-23.63 Million | $11.70 Million | ▼ -66.7% |
| 2023 | -1.21x | $-15.97 Million | $13.18 Million | ▼ -26.9% |
| 2022 | -0.96x | $-11.67 Million | $12.22 Million | ▲ +36.3% |
| 2021 | -1.50x | $-14.28 Million | $9.51 Million | ▼ -39.3% |
| 2020 | -1.08x | $-16.24 Million | $15.08 Million | ▲ +85.6% |
| 2019 | -7.49x | $-15.63 Million | $2.09 Million | ▼ -59.7% |
| 2018 | -4.69x | $-11.15 Million | $2.38 Million | ▲ +45.2% |
| 2017 | -8.56x | $-7.09 Million | $828.74K | ▼ -39.0% |
| 2016 | -6.16x | $-4.56 Million | $741.16K | ▼ -1705.1% |
| 2015 | -0.34x | $-49.88K | $146.29K | ▲ +96.8% |
| 2014 | -10.54x | $-41.44K | $3.93K | ▲ +12.6% |
| 2013 | -12.06x | $-62.19K | $5.16K | — |